IVA | Inventiva S.A. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.6806 - 2.7400
52 Week Range	1.5300 - 4.75
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	6,663
Average Volume	212,779
Shares Outstanding	86,902,896
Market Cap	238,113,935
Sector	Healthcare
Industry	Biotechnology
IPO Date	2020-07-10

Valuation
Profitability
Growth
Health
P/E Ratio	-1.26
Forward P/E Ratio	N/A
EPS	-2.17
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	123
Country	France
Website	IVA

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH), mucopolysaccharidoses (MPS), and other diseases. Its lead product candidate is Lanifibranor, which has completed Phase IIb clinical trial to treat NASH. The company also develops Odiparcil, which has completed Phase IIa clinical trial for the treatment of MPS VI subtype disease. In addition, it has a pipeline of earlier stage programs in oncology and other diseases. The company has strategic collaboration with AbbVie for the treatment of autoimmune diseases; and Boehringer Ingelheim International GmbH for developing new treatments for idiopathic pulmonary fibrosis. Inventiva S.A. was founded in 2011 and is based in Daix, France.

IVA's peers: CMPX, GLYC, GNLX, IMRX, IOBT, MLYS, ELYM, ANEB, JANX, RZLT, GLUE, NAMS, CGEM, ACLX, VTYX, IMCR, PCVX, DICE, VRCA, LIAN, EWTX, VIGL, IPHA, HCWB, INBX, MIST, NVCT, THTX, PMN

*Chart delayed

Analyzing fundamentals for IVA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see IVA Fundamentals page.

Watching at IVA technicals we can see that long-term trend is bearish, while middle-term trend is bullish, as well as bullish short-term trend. More technicals details can be found on IVA Technicals page.